SKBI Key Stats
| Income Statement | |
| Revenue TTM | 33.59M |
| Revenue Quarterly YoY Growth | -49.96% |
| EPS Diluted TTM | 0.8339 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | 6.212M |
| Profitability | |
| Gross Profit Margin Quarterly | 48.65% |
| Profit Margin Quarterly | -1.56% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 9.126M |
| Enterprise Value | 3.517M |
| PE Ratio TTM | 1.439 |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 0.0948 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.0594 |
| Free Cash Flow | 11.52M |
| Return on Equity | 6.68% |
SKBI News
- Skystar Bio - Pharmaceutical Company's CEO Discusses Q1 2013 Results - Earnings ... May 16
- Stocks Hitting 52-Week Lows Benzinga May 16
- Skystar Bio Pharmaceutical Co. (SKBI) Reports Q1 EPS of $0.09 Street Insider May 16
- Skystar Bio-Pharmaceutical Reports First Quarter 2013 Results Marketwired May 16
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report May 15
- Skystar to File Financial Results for First Quarter of 2013 on Wednesday, May 15... May 14
- Form 10 K for Skystar Bio-Pharmaceutical Company Apr 24
- Skystar Bio-Pharmaceutical Reports Fiscal Year 2012 Financial Results Marketwire Apr 2
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-K, Annual Report Apr 1
- Skystar to File Audited Financial Results for Full Fiscal Year 2012 on Monday Ap... Apr 1
SKBI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Skystar Bio-Pharmaceutical Company is down 55.07% over the last year vs S&P 500 Total Return up 31.99%, GlaxoSmithKline up 24.60%, and Tetraphase Pharmaceuticals down 0.24%.
SKBI Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these SKBI related companies
Pro Ratings for SKBI
Pro Report PDF for SKBI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download SKBI Pro Report PDF
Pro Strategies Featuring SKBI
Did Skystar Bio-Pharmaceutical Company make it into our Pro Portfolio Strategies?
SKBI Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Major
Other SKBI Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SKBI | 1.20 | -0.05 | -4.00% | 9.126M |
